Sign in →

Test Code P2Y12P P2Y12 Inhibition Assay

Important Note

1.8mL Pediatric tube is not acceptable for this test.

Specimen and Container/Tube

Specimen Type: Whole Blood

Preferred Specimen: 2.7mL Blue Top Tube, 3.2% Sodium Citrate

Other Acceptable specimens: N/A

Specimen Handling and Transport Instructions

UCMC Onsite Instructions: 

Collect specimen per standard collection procedure and send to laboratory immediately. 

 

NOTE: Once each blue top tube is completely filled, gently invert the sample tube at least five times to ensure complete mixing of the contents.

 

UCMC Offsite and UC MedLab Outreach Instructions: 

  • Whole blood sample must arrive in the laboratory within three hours of specimen collection.
  • Draw two 2.7mL blue top tubes.
  • Once each blue top tube is completely filled, gently invert the sample tube at least five times to ensure complete mixing of the contents.
  • Do not centrifuge samples. Centrifuged samples will be rejected.
  • Send samples Room Temperature. Refrigerated or frozen samples will be rejected. 

Rejection Criteria

  • Common specimen rejected situations include: incorrect specimen type, insufficient volume, missing or incomplete specimen identifiers, incorrect specimen transport, or specimens outside stability limits. 
  • Specimens that have wrong ratio of blood to anticoagulant (fill volume), clotted or grossly hemolyzed.

Reference Values

 

Test

Age

Sex

Reference Range

P2Y12

ALL

ALL

210 - 325 PRU

Critical Values

Analyte

Unit

Low

High

Age

N/A

N/A

N/A

N/A

N/A

CPT Codes

85576 X2

LOINC Codes

53813-2

Volume

Preferred Volume: Two 2.7 mL Blue Top Tubes, 3.2% Sodium Citrate

 

Minimum Volume: Two 2.7 mL Blue Top Tubes, 3.2% Sodium Citrate

Specimen Stability

Storage Temperature

Stability

Room temperature

4 hours

Refrigerated

not acceptable

Frozen

not acceptable

Collection Instructions

  • Collect specimen per standard laboratory collection procedures. 
  • Once each blue top tube is completely filled, gently invert the sample tube at least five times to ensure complete mixing of the contents.
  • Given the critical importance of platelets remaining unactivated prior to being exposed to the ADP stimulus in the course of this assay procedure, it is vital that the venipuncture be smooth and the blood flows readily. If these criteria are not achieved, the tube should be discarded and another venipuncture performed.
  • It is also essential to follow the proper Order of Draw.

Test Components

P2Y12 Inhibition

 

Clinical Indications

Measuring residual platelet function in patients on P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor)

Methodology

Platelet aggregation

Additional Information

This test is intended to evaluate the degree of functional platelet inhibition achieved following administration of P2Y12 receptor antagonist drugs. Whenever possible, it is strongly recommended to perform this test prior to institution of such therapy in order to provide a baseline from which achieved percent inhibition of response can subsequently be ascertained after the patient has begun receiving the antagonist drug.

Note: For platelet counts outside the range of 120,000/uL-500,000/uL, nonspecific interference at the analytical testing level may potentially produce misleading results with respect to P2Y12 receptor antagonism. Testing must be performed within 4 hours after the sample is drawn.

Turnaround Time

Turnaround times are relative to the time the specimen is received in the test laboratory. 

STAT Turnaround Time: N/A

 

Routine Turnaround Time: 4 hours

 

Testing Schedule: 7 days a week, 5:00 am to 10:30 pm

Synonyms/Keyword Search

Plavix Monitoring; P2Y12 inhibitors;

clopidogrel; prasugrel; ticagrelor

Last Review Date

05/28/2024